Home » Newsletters » BioWorld Science

BioWorld Science

May 8, 2009

View Archived Issues

Vasopressin V2 receptor antagonist shows potential for treatment of ascites in cirrhotic patients

ITMN-191 and R-7128 combination reduces development of HCV resistance

Potent dual HCV/HIV replication inhibitors RO-0622, RO-9187 identified

Novel compounds for the treatment of pain discovered by Daiichi Sankyo

Researchers describe first bivalent humanized IgG1 antibody directed against human c-Met

Gene therapy Ad-IFNalpha/Syn3 safe and well tolerated in phase I study in bladder cancer

Topical AS-101 shows promise in treating psoriasis

Skin penetration of antifungal agents increased with the addition of NB-002

Novavax initiates enrollment in phase II clinical trial of VLP seasonal influenza vaccine

Replikins begins production of synthetic H1N1 swine flu vaccine

Merck initiates phase III SETTLE trial of safinamide in Parkinson's disease

AcelRx commences phase II clinical trial of ARX-01 Sufentanil NanoTab PCA System

Nymox begins enrollment into second phase III clinical trial of NX-1207 for BPH

Clavis reports preclinical data that differentiate CP-4200 from current standard cancer therapy

BioInvent reports phase I results for its therapeutic antibody BI-204

Anthera reports favorable results from phase II clinical trial of varespladib in ACS

Pierre Fabre initiates clinical trials of a pediatric beta-blocker for infantile hemangioma

D-Pharm submits IND and SPA to FDA for phase III trial of DP-b99 in acute stroke

Enzon establishes recommended dose of cancer drug PEG-SN38 for phase II studies

Intravitreal ARC-1905 combined with ranibizumab shows no toxicity in phase I trial

Pharmalucia claims novel compounds for the treatment of bacterial infections

Korea Research Institute of Chemical Technology describes novel inhibitors of ischemic cell death

Amsterdam Molecular treats first patient in preregistration clinical trial of Glybera

Oxygen Biotherapeutics files orphan drug application with FDA for Oxycyte

FDA grants priority review to Wyeth's BLA for pneumococcal vaccine Prevnar 13

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...